HSV-1 Oncolytic Virus Targeting CEACAM6-Expressing Tumors Using a Bispecific T-Cell Engager
Y. M. Murad, I.-F. Lee, X. Liu, Z. Delwar, J. Ding, G. Liu, O. Tatsiy, D. Chouljenko, G. Hussack, H. Van Faassen, W. W.-G. Jia
This paper describes a novel oncolytic virus encoding a bispecific T-cell engager targeting CEACAM6-expressing tumors, showing enhanced anti-tumor efficacy and safety in vitro and in vivo.
bioRxiv · Jan 2, 2023 · PreprintCancer Biology